{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:03:15Z","timestamp":1788217395893,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1124\/molpharm.121.000333","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T18:36:00Z","timestamp":1631212560000},"page":"548-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites"],"prefix":"10.1016","volume":"100","author":[{"given":"Siennah R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley M.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.121.000333_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: an update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"key":"10.1124\/molpharm.121.000333_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11095-020-02842-8","article-title":"Repurposing quaternary ammonium compounds as potential treatments for COVID-19","volume":"37","author":"Baker","year":"2020","journal-title":"Pharm Res"},{"key":"10.1124\/molpharm.121.000333_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/molpharm.121.000333_bib4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/acs.jcim.5b00143","article-title":"Open source Bayesian models. 1. Application to ADME\/Tox and drug discovery datasets","volume":"55","author":"Clark","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1124\/molpharm.121.000333_bib5","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.jcim.5b00144","article-title":"Open source Bayesian models. 2. Mining a \u201cBig Dataset\u201d to create and validate models with ChEMBL","volume":"55","author":"Clark","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1124\/molpharm.121.000333_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1124\/molpharm.121.000333_bib7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","article-title":"Ebola RNA persistence in semen of Ebola virus disease survivors\u2013final report","volume":"377","author":"Deen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.121.000333_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1124\/molpharm.121.000333_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-020-02799-8","article-title":"Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond","volume":"37","author":"Ekins","year":"2020","journal-title":"Pharm Res"},{"key":"10.1124\/molpharm.121.000333_bib10","doi-asserted-by":"crossref","first-page":"e01711","DOI":"10.1128\/AAC.01711-17","article-title":"Efficacy of tilorone dihydrochloride against Ebola virus infection","volume":"62","author":"Ekins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/molpharm.121.000333_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00440-20","article-title":"Tilorone, a broad-spectrum antiviral for emerging viruses","volume":"64","author":"Ekins","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/molpharm.121.000333_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat Mater"},{"key":"10.1124\/molpharm.121.000333_bib13","unstructured":"Gilead Sciences I (2020) Veklury (remdesivir) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214787Orig1s000lbl.pdf Accessed [April 20, 2021)."},{"key":"10.1124\/molpharm.121.000333_bib14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2009.12.039","article-title":"Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy","volume":"52","author":"Hofer","year":"2010","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"10.1124\/molpharm.121.000333_bib15","doi-asserted-by":"crossref","first-page":"S622","DOI":"10.1093\/infdis\/jiu328","article-title":"Origins of HIV-infected leukocytes and virions in semen","volume":"210","author":"Houzet","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1124\/molpharm.121.000333_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of Remdesivir, a SARS-CoV-2 replication inhibitor","volume":"60","author":"Humeniuk","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/molpharm.121.000333_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1124\/molpharm.121.000333_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"},{"key":"10.1124\/molpharm.121.000333_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/jpet.113.203265","article-title":"Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1","volume":"346","author":"Klein","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000333_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/molpharm.121.000333_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104908","article-title":"Repurposing Pyramax\u00ae, quinacrine and tilorone as treatments for Ebola virus disease","volume":"182","author":"Lane","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/molpharm.121.000333_bib22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/acsmedchemlett.0c00298","article-title":"Toward the target: tilorone, quinacrine, and pyronaridine bind to Ebola virus glycoprotein","volume":"11","author":"Lane","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/molpharm.121.000333_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1124\/molpharm.121.000333_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104863","article-title":"Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig","volume":"181","author":"Lane","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/molpharm.121.000333_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8292","article-title":"Clinical characteristics and results of semen tests among men with Coronavirus Disease 2019","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1124\/molpharm.121.000333_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/FTD.0b013e31811fef29","article-title":"Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen","volume":"29","author":"Lowe","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1124\/molpharm.121.000333_bib27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/molpharm.121.000333_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/molpharm.121.000333_bib29","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/REP-18-0338","article-title":"Transepithelial transport across the blood-testis barrier","volume":"156","author":"Miller","year":"2018","journal-title":"Reproduction"},{"key":"10.1124\/molpharm.121.000333_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.121.000423","article-title":"Multiple computational approaches for predicting drug interactions with human equilibrative nucleoside transporter 1","volume":"49","author":"Miller","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/molpharm.121.000333_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/molpharm.120.000169","article-title":"Predicting drug interactions with human equilibrative nucleoside transporters 1 and 2 using functional knockout cell lines and Bayesian modeling","volume":"99","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000333_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside transporter proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1124\/molpharm.121.000333_bib33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/er.2014-1101","article-title":"The mammalian blood-testis barrier: its biology and regulation","volume":"36","author":"Mruk","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1124\/molpharm.121.000333_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2010.11.007","article-title":"Emerging role for drug transporters at the blood-testis barrier","volume":"32","author":"Mruk","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.121.000333_bib35","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.121.000333_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14787210.2020.1792291","article-title":"Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine \u2013 from HIV-1 infection to COVID-19","volume":"18","author":"Naghipour","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1124\/molpharm.121.000333_bib37","unstructured":"National Library of Medicine National Clinical Trial (May 2020) (U.S.) The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405739"},{"key":"10.1124\/molpharm.121.000333_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/pharmaceutics13030369","article-title":"Interaction of remdesivir with clinically relevant hepatic drug uptake transporters","volume":"13","author":"Nies","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/molpharm.121.000333_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/molpharm.121.000333_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1006\/bbrc.2000.4205","article-title":"Differential expression of human nucleoside transporters in normal and tumor tissue","volume":"280","author":"Pennycooke","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/molpharm.121.000333_bib41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/QAD.0b013e328353b11b","article-title":"Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men","volume":"26","author":"Politch","year":"2012","journal-title":"AIDS"},{"key":"10.1124\/molpharm.121.000333_bib42","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1021\/acsomega.0c05996","article-title":"Repurposing the Ebola and Marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV-2 and potential mechanisms","volume":"6","author":"Puhl","year":"2021","journal-title":"ACS Omega"},{"key":"10.1124\/molpharm.121.000333_bib43","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41467-018-04444-w","article-title":"Male germ cells support long-term propagation of Zika virus","volume":"9","author":"Robinson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1124\/molpharm.121.000333_bib44","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"Sagara","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/molpharm.121.000333_bib45","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1124\/mol.117.111443","article-title":"Assessment of substrate-dependent ligand interactions at the organic cation transporter OCT2 using six model substrates","volume":"94","author":"Sandoval","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000333_bib46","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.121.000333_bib47","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2214-109X(16)30175-9","article-title":"Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data","volume":"4","author":"Soka","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1124\/molpharm.121.000333_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/pharmaceutics13010081","article-title":"Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters","volume":"13","author":"Telbisz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/molpharm.121.000333_bib49","unstructured":"U.S. Department of Health and Human Services (2020) In Vitro Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. Docket Number: FDA-2017-D-5961. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions"},{"key":"10.1124\/molpharm.121.000333_bib50","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/cid\/ciw202","article-title":"Ebola virus persistence in semen of male survivors","volume":"62","author":"Uyeki","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1124\/molpharm.121.000333_bib51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.121.000333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:48:19Z","timestamp":1739954899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24011891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0026895X24011891"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.121.000333","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.121.000333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}